Funding for this research was provided by:
National Institute on Aging (AG055184)
Received: 10 September 2018
Accepted: 20 December 2018
First Online: 5 January 2019
Ethics approval and consent to participate
: The study protocol was approved by the Vanderbilt University Institutional Review Board. All participants provided written informed consent before participating in the study.
: Not applicable.
: JCF, LMP, and JAR are employed by and NNA is co-founder and part owner of Metabolic Technologies, Inc., which has executed an agreement for the rights to license the intellectual property for 2-hydroxybenzylamine from Vanderbilt University. JSD and RDM are employed by Sano Informed Prescribing, which received payment for services provided for this study. WSA received payment for the clinical pharmacokinetic analysis.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.